NCT06994117AVAILABLE
Expanded Access for Mezigdomide
Sponsor: Bristol-Myers Squibb
No open prediction endpoints
Endpoints are classified and published by ProgramSignal analysts.
Request endpoint coverageKey Facts
Study type
EXPANDED_ACCESS
Conditions
—
Interventions
Mezigdomide
Enrollment
—
Primary completion
—
Study completion
—
First posted
May 2025
Last updated
Dec 2025
Eligibility Criteria
Inclusion Criteria: \- Exclusion Criteria: \-
✦ Analyst Commentary
Expert commentary on why this trial matters and what to watch for.
Request coverage →